This approach may enable a quicker response to emerging disease outbreaks, as is evident from the swift pursuit of RNA vaccine candidates for the global SARS-CoV-2 pandemic. Both conventional and self-amplifying RNAs have shown protective immunization in preclinical studies against multiple infectious ...
RNA vaccine candidates for the global SARS-CoV-2 pandemic. Both conventional and self-amplifying RNAs have shown protective immunization in preclinical studies against multiple infectious diseases including influenza, RSV, Rabies, Ebola, and HIV-1. Self-amplifying RNAs have shown enhanced antigen ...
self-amplifying alphavirus Introduction RNA is a potent platform for gene delivery, both vaccine antigens and therapeutic proteins, although there are necessarily differences in the interaction of the immune system with the expressed proteins. Self-amplifying RNA (saRNA) offers a considerable advantage ...
Figure 6. A Single Dose of Self-Amplifying RNA Vaccine Gives Equivalent Protection to Electroporated DNA and Greater Protection than mRNA Encoding the Same Gene (A) BALB/c mice were primed i.m. with 1.5 μg Cal’09 H1N1 as DNA or self-amplifying RNA. RNA was delivered as a formulation...
The technology usesgenetic codecalled self-amplifying RNA (saRNA). This genetic information holds instructions to make a protein found on the outside of the coronavirus, called the spike protein. Once injected into the muscle of the arm, the cells make this spike protein, enabling the immune sy...
Self-amplifying mRNA (samRNA) is rapidly emerging as a well-tolerated, scalable and widely-applicable platform technology which can be used to develop multiple vaccines simply by changing the sequence of the antigen (the target ...
Revolutionizing Vaccine Development Rapid response to emerging diseases is critical when developing a vaccine. Long RNA (mRNA and saRNA) is at the forefront of vaccine development. Benefits of saRNA saRNA vaccines can be developed in a fraction of the time it takes to develop a conventional vaccine...
Here weshow that nonviral delivery of a 9-kb self-amplifying RNA encap-sulated within an LNP substantially increased immunogenicitycompared with delivery of unformulated RNA. This unique vaccinetechnology was found to elicit broad, potent, and protective im-mune responses, that were comparable to ...
[2] Spurred on by Moderna and Pfizer's success, a Belgian biotech has big ambitions for its self-amplifying RNA vaccine play. Retrieved September 8, 2021, from https://endpts.com/spurred-on-by-moderna-and-pfizers-success-a-belgian-biotech-has-big-ambitions-for-its-self-amplifying-rna-vacc...
Arcturus Therapeutics Holdings Inc. today shared topline data from an ongoing Phase 1/2/3 trial evaluating ARCT-154, Arcturus’ self-amplifying mRNA vaccine candidate against COVID-19 disease caused by the SARS-CoV-2 virus.